Current evidence supports a multimodal treatment pathway that can include education, individualized assessment, hearing aids, and advanced management approaches such as cognitive behavioral therapy (CBT).
Numerous studies show that tinnitus is widespread and often co-occurs with hearing loss. It is estimated that about 10–15% of the population experiences tinnitus, with the majority not finding it bothersome.1 Around 20% of those affected require medical support, and about 2% experience such strong impacts that daily life is significantly affected. Latest evidence also indicates that four in five people with tinnitus may have concurrent hearing loss.2
From assessment to therapy: Reducing tinnitus distress
There is currently no cure for tinnitus. However, there are many ways to support people with bothersome tinnitus.2 The aim of care is to reduce distress and overall burden. A standardized tinnitus assessment to characterize the individual burden—based on validated questionnaires—can provide the foundation for individualized counseling and further management strategies.

The current best-validated treatment is cognitive behavioral therapy (CBT), which aims to alter tinnitus-related maladaptive behavior and negative associations to lessen the impact of tinnitus.3 Access to psychological care such as CBT remains a challenge for many tinnitus patients,4 though an increasing number of validated digital tools now provide internet-based CBT options.
Hearing aids and multimodal care: Better outcomes for tinnitus patients
There is growing evidence that amplification through hearing aids can help tinnitus patients with hearing loss by improving speech understanding, enhancing hearing-related quality of life, and reducing tinnitus perception.5 Most modern hearing aids also include integrated tinnitus masking features that can provide additional support.
Dr. Maren Stropahl, Senior Director of Holistic Hearing Care at Sonova, emphasized: “There is growing evidence that the combination of treatments is more effective than single treatments, which suggests that multimodal, patient-centered approaches can provide the best relief.”6
- Physicians and ENT specialists interested in clinical resources, collaborative programs, or educational opportunities can find additional information in the physician resources section at AudioNova.com or contact AudioNova at hello@audionova.com.
AudioNova US
AudioNova US is committed to helping people hear and live better. As Sonova’s hearing care retail brand in the United States, AudioNova operates nearly 400 clinics across 37 states. Local hearing care experts support individuals at every stage of their hearing journey, offering clear information, easy access, and personalized care in clinics or via telehealth. More information is available at AudioNova.com.
About Sonova
Sonova is a global leader in innovative hearing care solutions, ranging from personal audio devices and wireless communication systems to audiological care services, hearing aids, and cochlear implants. Founded in 1947 and headquartered in Stäfa, Switzerland, Sonova operates through four businesses—Hearing Instruments, Audiological Care, Consumer Hearing, and Cochlear Implants—and core brands including Phonak, Unitron, AudioNova, Sennheiser (under license), and Advanced Bionics, as well as recognized regional brands. Sonova serves consumers in more than 100 countries.
In the 2024/25 financial year, Sonova generated sales of CHF 3.9 billion, with a net profit of CHF 547 million. Approximately 18,000 employees worldwide contribute to Sonova’s vision of a world where everyone enjoys the delight of hearing.
Sonova has a long-standing commitment to innovation and was ranked No. 12 among the most innovative companies in Europe in 2025 by Fortune magazine, selected from 300 companies across 21 countries and 16 industries.
For more information, visit www.sonova.com.
References
1 Jarach, C. M., et al. (2022). Global prevalence and incidence of tinnitus: A systematic review and meta-analysis. JAMA Neurology, 79(9), 888–900. https://doi.org/10.1001/jamaneurol.2022.2189
2 Cima, R. F., et al. (2019). A multidisciplinary European guideline for tinnitus: Diagnostics, assessment, and treatment. HNO, 67(1), 10–42. https://doi.org/10.1007/s00106-019-0633-7
3 Langguth, B., et al. (2023). Tinnitus guidelines and their evidence base. Journal of Clinical Medicine, 12(9), Article 3087. https://doi.org/10.3390/jcm12093087
4 Subotic-Kerry, M., et al. (2025). While they wait: A cross-sectional survey on wait times for mental health treatment. BMJ Open, 15:e087342. https://doi.org/10.1136/bmjopen-2024-087342
5 Jacquemin, L., Gilles, A., & Shekhawat, G. S. (2022). Hearing more to hear less: A scoping review of hearing aids for tinnitus relief. International Journal of Audiology, 61(11), 887–895. https://doi.org/10.1080/14992027.2021.2007423
6 Schoisswohl, S., et al. (2025). Single versus combination treatment in tinnitus: An international randomized controlled trial. Nature Communications, 16, 10510. https://doi.org/10.1038/s41467-025-66165-1
Source: AudioNova US







